Medinfo - Find - Stratford May

Please note that Find will be retiring soon. Directory functionality will be replaced by the new UF Health Directory. If you have any questions about the Find retirement you can contact us here.


Faculty, Pharmacology / Therapeutics, Medicine

Complete Name: William Stratford May, Jr, M.D., Ph.D.

Phones:UF Business Telephone: (352) 273-7760

Shands Provider Number: (352) 733-0972

Postal:UF Business Mailing
    Po Box 100278
    Gainesville, FL 32610



Medical School
Georgetown University 

Johns Hopkins Hospital

Johns Hopkins Hospital

  • Cheng X, Byrne M, Brown KD, Konopleva MY, Kornblau SM, Bennett RL, May WS. PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice. Blood. 2015 Sep 24;126(13):1585-94.
  • Byrne M, Bennett RL, Cheng X, May WS. Progressive genomic instability in the Nup98-HoxD13 model of MDS correlates with loss of the PIG-A gene product. Neoplasia. 2014 Aug;16(8):627-33.
  • Ai L, Kim WJ, Alpay M, Tang M, Pardo CE, Hatakeyama S, May WS, Kladde MP, Heldermon CD, Siegel EM, Brown KD. TRIM29 suppresses TWIST1 and invasive breast cancer behavior. Cancer Res. 2014 Sep 1;74(17):4875-87.
  • Liu X, Bennett RL, Cheng X, Byrne M, Reinhard MK, May WS Jr. PKR regulates proliferation, differentiation, and survival of murine hematopoietic stem/progenitor cells. Blood. 2013 Apr 25;121(17):3364-74.
  • Bennett RL, Carruthers AL, Hui T, Kerney KR, Liu X, May WS Jr. Increased expression of the dsRNA-activated protein kinase PKR in breast cancer promotes sensitivity to doxorubicin. PLoS One. 2012;7(9):e46040.
  • Bennett RL, Pan Y, Christian J, Hui T, May WS Jr. The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and activation, leading to G₁ arrest. Cell Cycle. 2012 Jan 15;11(2):407-17.


  • Dr. May’s focuses on discovery-driven research involving the molecular mechanisms by which hematopoietic growth factors regulate the cell signaling responsible for efficient cell growth of both normal and malignant/leukemic hematopoietic cells. Dr. May’s research is focused on regulation of apoptosis by Bcl2 and other anti- or pro-apoptotic factors. Dr. May also works on the three novel genes discovered by his laboratory: 1.) RAX (PKR-associated protein X) which is the only known cellular activator of PKR; 2.) JAZ (Just-another-zinc finger protein) which is a novel, direct activator of p53; and 3.)  KOS (kinase of embryonic stem cells) which is a negative regulator of Ras and a tumor suppressor gene. His research is funded by the NCI and NHLBI of the NIH.
  • Dr. May also acts as PI for the T32 Training Grant in Cancer Biology which sponsors pre-doctoral candidates and post-doctoral fellows.

There is additional contact information available for William May, but you are not authorized to see it. Use the LOGIN button inthe upper right of this page and you will be returned here after login.